Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Neurologic Other
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Neurologic Other
    Ginkgo Evaluation of Memory Study Fails to Show Benefit in Preventing Dementia in the Elderly - (DGNews)
    Routine Testing After Aneurysm Coiling Carries Low Risk - (DGNews)
    FDA Approves Rufinamide as Adjunctive Treatment for Lennox-Gastaut Syndrome - (DGNews)
    Earlier Jaundice Treatment Decreases Brain Injury in Preemies - (DGNews)
    Subthalamic nucleus stimulation in severe obsessive-compulsive disorder - (N Engl J Med)

    News archive

     Recent webcasts/CME - Neurologic Other
    Role of the Autonomic Nervous System in Atrial Fibrillation
    Delirium in the ICU: An Overview

    Webcasts/CME archive

     Recent cases - Neurologic Other
      Adalimumab Induced Mononeuritis Multiplex in a Patient with Refractory Rheumatoid Arthritis: A Case Report
      IgM Multiple Myeloma Presenting with Spinal Cord Compression Caused by a Plasmacytoma: A Case Report
      Postpartum Thunderclap Headache
      Extrapulmonary Small Cell Sarcinoma: Involvement of the Brain Without Evidence of Extracranial Malignancy by Serial PET/CT Scans
      Neurocognitive Deficits in a Patient with Small Cell Lung Cancer: A Case Report

      Cases archive
        




      my personal edition > neurologic other > news
      divider

        E-Mail this DGDispatch to a colleague

      DGDispatch


      OROS Formulation of Methylphenidate Does Not Worsen Tics in Children with Attention Deficit/Hyperactivity: Presented at ANA

      By Jill Stein

      SAN FRANCISCO, CA -- October 24, 2003 -- Long-term therapy with once-daily osmotic release oral system (OROS) methylphenidate (Concerta) has minimal, if any, impact on tics in children with attention-deficit/hyperactivity disorder (ADHD), researchers reported here on October 20th at the 128th Annual Meeting of the American Neurological Association.

      Donna Palumbo, MD, and colleagues, University of Rochester, Rochester, New York, United States, treated 407 children with ADHD using 18 mg, 36 mg, or 54 mg methylphenidate, taken once a day. Children with a history of mild or moderate tics were eligible for enrollment in the study.

      "Attention-deficit/hyperactivity disorder and tic disorders are both common neurobehavioural disorders in children and frequently occur together," Dr. Palumbo pointed out. "While stimulants are the recommended first-line pharmacotherapy for ADHD, controversy surrounds their use in children with ADHD who are considered at risk of tic disorders due to concerns that stimulants may induce or exacerbate tics."

      She added that these concerns are based on a limited number of studies that did not take into account the natural history of the disorders and which are contradicted by other research.

      During the first year of her study, Dr. Palumbo and colleagues found that the incidence of tics remained constant at about 5% per month, and most tics were not new in onset. Parental monthly reports over the first year indicated that in most cases the severity of tics remained unchanged or decreased from the prior month.

      During the 2-year study, 63 tic episodes were reported as adverse events in 9.8% of children -- most were reported during the first year.

      Most tics were mild or moderate in severity, and the mean total duration was similar for both mild and moderately severe tics, with 116 days and 108 days for mild and moderately severe tics, respectively.

      The risk of a tic episode was low, at 7%, in children with no history of tics. Even among those with a known history of tics, only one in three reported tics as an adverse event over the course of the study.

      Overall, the results suggest that long-term therapy with OROS methylphenidate has a negligible impact on tics in children with ADHD, Dr. Palumbo said.

      The study was supported by McNeil Consumer & Specialty Pharmaceuticals.


      [Study title: Once-Daily Dosing With the ORORS Formulation of Methylphenidate Has Minimal Impact on Tics in Children with ADHD. Abstract 24]



      E-Mail this DGDispatch to a colleague   To print, use this version






      All contents Copyright (c) 1995-2008 Doctor's Guide Publishing Limited. All rights reserved.



      The NTK initiative. Physicians helping physicians identify Need-To-Know science
         Feedback
      Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
      Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
      1
      2
      3
      4
      5
      6
      7
      Send